Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dianthus Therapeutics Inc (DNTH)

Dianthus Therapeutics Inc (DNTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,900,410
  • Shares Outstanding, K 54,449
  • Annual Sales, $ 2,040 K
  • Annual Income, $ -162,340 K
  • EBIT $ -178 M
  • EBITDA $ -184 M
  • 60-Month Beta 1.22
  • Price/Sales 2,400.73
  • Price/Cash Flow N/A
  • Price/Book 7.86

Options Overview Details

View History
  • Implied Volatility 65.35% (-0.20%)
  • Historical Volatility 77.22%
  • IV Percentile 16%
  • IV Rank 6.00%
  • IV High 229.28% on 08/25/25
  • IV Low 54.88% on 12/18/25
  • Expected Move (DTE 3) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.23
  • Today's Volume 130
  • Volume Avg (30-Day) 379
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 10,589
  • Open Int (30-Day) 9,261
  • Expected Range 94.91 to 94.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.17
  • Number of Estimates 6
  • High Estimate $-0.72
  • Low Estimate $-1.51
  • Prior Year $-0.82
  • Growth Rate Est. (year over year) -42.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
75.50 +25.71%
on 03/23/26
96.04 -1.18%
on 04/14/26
+17.05 (+21.90%)
since 03/13/26
3-Month
42.37 +124.00%
on 01/15/26
96.04 -1.18%
on 04/14/26
+48.62 (+105.03%)
since 01/14/26
52-Week
16.64 +470.54%
on 06/23/25
96.04 -1.18%
on 04/14/26
+76.20 (+407.27%)
since 04/14/25

Most Recent Stories

More News
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and WALTHAM, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to...

DNTH : 94.91 (+5.46%)
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEW YORK and WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing...

DNTH : 94.91 (+5.46%)
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering

NEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing...

DNTH : 94.91 (+5.46%)
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering

NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing...

DNTH : 94.91 (+5.46%)
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results

Early GO decision reached in CAPTIVATE ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A  Phase...

DNTH : 94.91 (+5.46%)
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A  Key objectives achieved:...

DNTH : 94.91 (+5.46%)
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to...

DNTH : 94.91 (+5.46%)
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and WALTHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to...

DNTH : 94.91 (+5.46%)
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference

NEW YORK and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to...

DNTH : 94.91 (+5.46%)
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

NEW YORK and WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to...

DNTH : 94.91 (+5.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Dianthus Therapeutics Inc. is a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics. Dianthus Therapeutics Inc., formerly known as Magenta Therapeutics Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 102.98
2nd Resistance Point 99.51
1st Resistance Point 97.21
Last Price 94.91
1st Support Level 91.44
2nd Support Level 87.97
3rd Support Level 85.67

See More

52-Week High 96.04
Last Price 94.91
Fibonacci 61.8% 65.71
Fibonacci 50% 56.34
Fibonacci 38.2% 46.97
52-Week Low 16.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.